About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the future of humanity.
https://weizmann-usa.org/blog/toxic-migration-cancer-cells-on-the-move/
Jul 20, 2018...
The road best traveled: finding supportive microenvironments helps cancer cells survive.
What do we have in common with Lake Michigan?
As Siddhartha Mukherjee writes in The New Yorker, the way cancer metastasizes through the body is similar to the way invasive zebra and quagga mussels have taken over that great lake, their expanding populations decimating the resident ecosystem. In their native Ukraine, however, the mussels are in balance with their environment.
https://weizmann-usa.org/news-media/feature-stories/the-tumor-microenvironment-s-big-impact/
Oct 23, 2018...
Dr. Ruth Scherz-Shouval
In order to execute the complex maneuvers of metastasizing and evading the body’s immune response, tumors need help. And they get that help from a surprising place: their healthy neighbors.
The noncancerous cells that surround cancer cells are known collectively as the tumor microenvironment, and include cells of the immune and blood systems and fibroblasts, which produce fibers such as collagen.
https://weizmann-usa.org/news-media/news-releases/looking-for-the-genes-that-drive-cancer/
Dec 01, 2012... Prof. Yardena Samuels of the Weizmann Institute’s Department of Molecular Cell Biology uses the power of DNA sequencing to identify new groups of genetic mutations involved in the deadliest form of skin cancer, melanoma. One of her discoveries, a mutation found in nearly one-fifth of melanoma cases, was particularly encouraging because it is located in a gene already targeted by a drug approved for certain types of breast cancer, and preliminary clinical trials are underway.
Jun 20, 2016...
Image via Shutterstock.com
The Israeli company Nucleix has developed a simple, inexpensive urine test to monitor bladder cancer, which has the highest lifetime treatment cost per patient of all types of cancer.
Bladder EpiCheck is expected to be available in Europe in the third quarter of 2016, says Nucleix President and Chief Operating Officer Opher Shapira. Right now, the product is undergoing advanced clinical trials in the Netherlands, Germany, Spain and Israel.
https://weizmann-usa.org/news-media/news-releases/disrupted-nitrogen-metabolism-might-spell-cancer/
Aug 14, 2018... Staining of normal liver tissue (upper row, second image from left) reveals high levels of four different urea cycle enzymes (brown or reddish-brown), whereas liver cancer samples (bottom row, second image from left) have low levels of these enzymes. In contrast, markers for cell growth are low in the normal tissue (upper row, left) and extremely high in the liver cancer (bottom row, left). Image generated with the help of Dr. Raya Eilam
https://weizmann-usa.org/news-media/news-releases/a-new-route-to-blocking-children-s-bone-cancer/
Oct 02, 2019...
The lungs of a mouse with untreated Ewing sarcoma (left) contain numerous tumor cells (shown by luminescent colors) that have spread from the bone; the lungs of a mouse treated with a drug reducing the synthesis of glucocorticoids are almost free from the sarcoma (right)
REHOVOT, ISRAEL—October 2, 2019—Ewing sarcoma is a bone cancer that appears mainly in teenagers. Caused by a single defective gene, once it spreads to distant organs it is hard to treat. Researchers at the Weizmann Institute of Science have now discovered molecular interactions underlying Ewing sarcomas and proposed a potential treatment that has shown promise in a study in mice. These findings were published in Cell Reports.
Aug 30, 2017...
Weizmann Institute’s Prof. Zelig Eshhar holds a board that illustrates how the cancer treatment works with mice. Aug. 29, 2017 (Shoshanna Solomon/Times of Israel)
Prof. Zelig Eshhar’s phones haven’t stopped ringing since the news broke two days ago that Israeli-founded Kite Pharma would be bought by US pharma company Gilead Sciences Inc. for a whopping $12 billion.
Eshhar, a researcher at Israel’s Weizmann Institute of Science, developed the technology which is at the heart of Monday’s acquisition. He is also on Kite’s scientific advisory board, and was one of the first people to get a call from Kite CEO and founder, Israeli-American oncologist Arie Belldegrun, after the deal was signed.
Jun 02, 2006... Unlike most cancers, colon cancer can be detected early, before symptoms arise, with routine screening tests such as colonoscopy. Despite this, the disease remains among the most common and deadly cancers in the U.S., and its incidence in Israel has more than doubled in the past 30 years. But if an international research effort involving Weizmann Institute scientists reaps the benefits its collaborators hope for, better diagnosis of colon cancer and more individualized therapies for patients could be on the horizon.
May 27, 2013...
Prof. Yosef Yarden in his Weizmann lab.
Breast cancer can be curable if it’s caught soon enough—unless it is the “triple negative” type more likely to target young, black or Hispanic women.
Israeli researchers from the Weizmann Institute of Science in Rehovot are opening a new window of hope for the daughters and granddaughters of women diagnosed with triple-negative breast cancer. The cancer carries a strong genetic link and it is also found in people of Jewish Ashkenazi (Eastern European) ancestry.
https://weizmann-usa.org/news-media/feature-stories/shining-a-light-on-skin-cancer/
May 12, 2015...
May is Melanoma/Skin Cancer Detection and Prevention Month: the perfect opportunity to learn more about the disease – and what the Weizmann Institute of Science is doing to help.
Did you know that skin cancer is the most common cancer in America? And that it’s been on the rise for more than 30 years? Melanoma is one form of skin cancer, and while it’s not the most common type, it is the deadliest. The American Cancer Society currently estimates that more than 135,000 new cases of melanoma are diagnosed each year in the U.S. alone. It’s predicted that, in 2015, about 74,000 of these will be invasive melanomas, with more occurring in men than women.
©2023 American Committee for the Weizmann Institute of Science
